Eisai seeks label expansion in Japan for Lenvima in HCC

Eisai Co. Ltd. (Tokyo:4523) submitted an application in Japan to expand the label for Lenvima lenvatinib mesylate (E7080) to treat hepatocellular carcinoma (HCC). Eisai plans to submit applications for Lenvima to treat HCC in the U.S. and Europe by the end of September and in China by the end of 1Q18...